What happened
Pharmicell disclosed a supply contract with Doosan, worth US$5.52M, about 6.49% of its recent annual revenue, running through Dec 2026.
For context, this single contract equals about 6.49% of the company's most recent annual revenue.
| Counterparty | Doosan |
|---|---|
| Contract value | US$5.52M |
| vs. recent revenue | 6.49% |
| Through | Dec 2026 (from Oct 2026) |
| Filed | 2026-10-14, Supply contract signed |
| Source | DART rcept 20261014800148 → open original filing |
Source: DART. Information only, not investment advice.